

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/351330689>

The possibilities of using the effects of ozone therapy in neurology

Article · March 2021

CITATION

1

READS

521

3 authors, including:



Ján Mašán

University of St. Cyril and Methodius of Trnava - Univerzita sv. Cyrila a Metoda

11 PUBLICATIONS 5 CITATIONS

[SEE PROFILE](#)



Daria Rabarova

University of Trnava

1 PUBLICATION 1 CITATION

[SEE PROFILE](#)

REVIEW ARTICLE

THE POSSIBILITIES OF USING THE EFFECTS OF OZONE THERAPY IN NEUROLOGY

Ján MASAN^{1,2,3}, Miron SRAMKA², Daria RABAROVA³

¹ University of St. Cyril and Methodius in Trnava, Slovak Republic.

² St. Elizabeth University of Health Care and Social Work in Bratislava, Slovak Republic.

³ Trnava University in Trnava, University Hospital Trnava, Slovak Republic.

Correspondence to: h.Doc. MUDr. Ján Mašán, PhD.

St. Elizabeth University of Health Care and Social Work in Bratislava, Slovak Republic

E-MAIL : masanjan@gmail.com

Keywords: Ozone therapy. Major ozone therapy. Neurodegenerative disorders. Antioxidant system. Oxidative stress biomarkers. Multiple sclerosis. Stroke. Neuropathy. Phantom limb pain. Polyneuropathy.

Abstract

OBJECTIVES: The beneficial effects of ozone therapy consist mainly of the promotion of blood circulation: peripheral and central ischemia, immunomodulatory effect, energy boost, regenerative and reparative properties, and correction of chronic oxidative stress. Ozone therapy increases interest in new neuroprotective strategies that may represent therapeutic targets for minimizing the effects of oxidative stress.

METHODS: The overview examines the latest literature in neurological pathologies treated with ozone therapy as well as our own experience with ozone therapy. The effectiveness of treatments is connected to the ability of ozone therapy to reactivate the antioxidant system to address oxidative stress for chronic neurodegenerative diseases, strokes, and other pathologies. Application options include large and small autohemotherapy, intramuscular application, intra-articular, intradiscal, paravertebral and epidural, non-invasive rectal, transdermal, mucosal, or ozonated oils and ointments. The combination of different types of ozone therapy stimulates the benefits of the effects of ozone.

RESULTS: Clinical studies on O₂-O₃ therapy have been shown to be efficient in the treatment of neurological degenerative disorders, multiple sclerosis, cardiovascular, peripheral vascular, orthopedic, gastrointestinal and genitourinary pathologies, fibromyalgia, skin diseases/wound healing, diabetes/ulcers, infectious diseases, and lung diseases, including the pandemic disease caused by the COVID-19 coronavirus.

CONCLUSION: Ozone therapy is a relatively fast administration of ozone gas. When the correct dose is administered, no side effects occur. Further clinical and experimental studies will be needed to determine the optimal administration schedule and to evaluate the combination of ozone therapy with other therapies to increase the effectiveness of treatment.

Abbreviations: O₃ – ozone, GSH – glutathione, NADPH – nicotinamide adenine dinucleotide, (SOD) – superoxide dismutase, PUFA – unsaturated fatty acids, LOP – lipid ozonation products, ARE – antioxidant response elements, ATP – adenosine triphosphate, ROS – reactive oxygen species, DNA – deoxyribonucleic acid, NADH – nicotinamide adenine dinucleotide

INTRODUCTION

Van Mauren was first to discover the distinctive odor of O₃ in 1785 (Altman 2007). However, its first identification as a distinct chemical compound was made by Schönbein in Basel in 1840. In 1896, Nikola Tesla patented a generator for producing ozone. The use of ozone became normal practice after the studies of Dr. H.H. Wolff. In 1915, during World War I, ozone was used to treat war wounds. Following Bocci's studies, ozone therapy has been incorporated into the treatment of chronic inflammatory diseases in the orthopedic field. When used in appropriate doses, it has been shown to be effective in inducing well-tolerated oxidative stress. Ozone is a metastable substance and must be generated on-site. Contraindication of O₃ therapy is lung inhalation, activating factors triggering an inflammatory response (Bocci 2006; Pryor et al. 2019). Jacobs (1982) carefully examined all the possible negative effects of ozone therapy. Despite the famous "toxicity" of ozone, it appears that the incidence is only 0.0007%, one of the lowest in medicine. Four deaths due to direct IV injection of the gas were included in his data but, since 1982, other deaths due to malpractice have occurred, of which at least three were in Italy (Bocci 2010).

It is currently applied in a wide range of medical fields: surgery, orthopedics, neurology, oncology, dermatology, cardiology, psychiatry, radiology, rheumatology, gynecology, gastroenterology, angiology, dentistry, etc.

The effects of medical ozone as a substance can be attributed to those defined by hormesis (from the Greek word *hormáein* = to set in motion), i.e. referring to the hypothesis regarding the beneficial effects of low doses. At the same time, it triggers a response with high doses, thus increasing the body's resistance.

Induction of the response to stress by short low doses usually protects the body for a longer period of time and against other possible types of doses (Rattan et al. 2009). The administration of O₃ therapy varies based on treatment goals and treatment focus. Ozone therapy combines a mixture of oxygen (O₂)-O₃ with a diverse therapeutic range (10–80 µg/ml of gas per ml of blood) (Bocci 2006). Human blood contains a large number of antioxidants such as uric acid, ascorbic acid, cysteine, glutathione, albumin, certain chelating proteins such as albumin, and enzymes such as catalase, the redox system of GSH, NADPH (nicotinamide adenine dinucleotide), and superoxide dismutase (SOD) (Bocci et al., 2005).

Like any other gas, ozone dissolves upon contact with body fluids according to Henry's Law in relation to temperature, pressure, and ozone concentration. It reacts immediately as soon as it is dissolved: O₃ + biomolecules → O₂ + O₂ + energy. Atomic oxygen behaves as a reactive atom. The fundamental ROS (reactive oxygen species) molecule is hydrogen peroxide H₂O₂, which is a non-radical oxidant able to act as an ozone Messenger responsible for eliciting several biological and therapeutic effects. In physiological amounts, they act as regulators of signal transduction and represent important mediators of host defense and immune responses (Dattilo et al. 2015).

The reaction of O₃ with water causes the formation of one mole of hydrogen peroxide (H₂O₂) and two moles of lipid oxidation products with polyunsaturated fatty acids (PUFA), forming a mixture of lipid ozonation products (LOP) (Barone et al. 2015) including lipoperoxyl radicals (Inal et al. 2011). Moderate oxidative stress caused by O₃ increases the activation of the transcription factor of the pathway-mediated nuclear factor-related erythroid factor 2 (Nrf2) (Bocci et al. 2015, Re et al. 2014), which is responsible for activating the transcription of antioxidant response elements (ARE). After their induction, the concentration of antioxidant enzymes increases in response to the transient oxidative stress O₃ (Bocci et al. 2015).

POTENTIAL APPLICATION OF OZONE THERAPY

Vascular and Haematological Modulation The production of antioxidant enzymes affects the whole body (Gonzalez et al. 2004; Valacchi 2000). O₃ is a stimulator of O₂ transmembrane flow. Increased intracellular O₂ levels secondarily form the mitochondrial respiratory chain ([Madej et al. 2007](#)). In red blood cells, O₃ increases phosphofructokinase activity, thereby increasing the rate of glycolysis. Increased glycolytic rate increases ATP and 2,3-diphosphoglycerate (2,3-DPG) in the cell. Following a long treatment cycle of the elderly, Bocci et al. 2011 noted a significant increase in the 2,3-diphosphoglycerate level in oxyhaemoglobin. As a result of the Bohr effect, its dissociation curve shifts to the right, making it easier to transfer oxygen. Under physiological conditions, the endothelium regulates vascular tone (Molinari et al. 2017). Ozonised blood increases the release of prostacyclin (PGI₂) and angiopoietins, both important factors in improving ischemic vasculopathy (Fernández et al. 2008; Elvis et al. 2011).

The correction of chronic oxidative stress via the increase of antioxidant enzymes can increase erythroblast differentiation. This leads to a progressive increase in erythrocytes and preconditions them to having resilience towards oxidative stress, to an increase of erythrocytes with improved metabolic properties, as well as ensuring that young erythrocytes contain more G6PDH than older cells generated prior to the treatment, which is a type of “super-gifted erythrocytes” capable of correcting hypoxia in vascular diseases (Chang et al. 2005). An improvement in blood circulation and oxygen supply to ischemic tissues has been recorded, leading to an increased supply of O₂ to hypoxic tissues (Brigelius-Flohé et al. 2011).

Activation of the Immune System. O₃ has been shown to react with antioxidants and alter peroxidation compounds. H₂O₂ has been shown to act as a regulatory step in signal transduction by diffusing into immune cells and by facilitating a myriad of immune responses (Gulmen et al. 2013; Caliskan et al. 2011). An increase in interferon, tumor necrosis factor, and interleukin (IL)-2 was observed. IL-2 increases were initiated by immune response mechanisms (Elvis 2011). In addition, H₂O₂ activates nuclear factor-kappa B (NF-κB) and transforms growth factor-beta (TGF-β), thus increasing the immunoactive release of cytokines and tissue refurbishment.

After each restarted therapy, a small percentage of immune cells are activated and these cells release cytokines into the micro-environment, activating neighboring cells and, as a result, slowly enhancing immune responses. Only submicromolar concentrations can reach

all organs, particularly bone marrow, liver, central nervous system, endocrine glands, etc., where they act as signaling molecules of an ongoing acute oxidative stress (Mancuso et al. 1997). These molecules can elicit the upregulation of antioxidant enzymes. The induction of HO-1 has been described as one of the most important antioxidant defense and protection enzymes. Throughout the treatments, LOP acts as an acute oxidative stressor in the bone marrow micro-environments and thus activates the release of metalloproteinases, of which particularly MP-9 may favor the detachment of staminal cells. These cells, once in the blood circulation, may be attracted to sites where a previous injury has taken place (Mancuso et al. 2008).

Lahodny (2021) collected ten blood samples with 70 µg/ml of ozone and reinfusion from a patient as part of a session to implement the therapeutic concept. This therapy generated a significant activation of stem cells, and subsequent rapid healing of wounds and inflammation were documented in patients (Rowen 2018). Thanks to this therapy, a several-year defect was cured in a mere 14 days (Mašán 2018).

Ozone therapy has a neuroimmunomodulatory effect, it activates the psychosomatic system, thus allowing the release of the growth hormone ACTH-cortisol, neurotonic hormones, and neurotransmitters. We clarified why patients report a feeling of euphoria and wellness during therapy: the disappearance of asthenia and depression, a reduction of pessimism syndrome, associated with a lack of side effects, represent positive results (Fernández et al. 2008; Mancuso 2017).

CLINICAL APPLICATION OF OZONE THERAPY IN NEUROLOGY

The first beneficial effects of ozone in the treatment of neurological disorders refer to the treatment of headaches and facial pain associated with pathological changes in the optic thalamus. Ozone is used to treat allodynia, neuropathic pain, and hyperalgesia (Kal et al. 2017; Hu et al. 2018).

Neurodegenerative diseases – Parkinson’s disease, Alzheimer’s and Wilson’s disease, senile and vascular dementia, amyotrophic lateral sclerosis, optic nerve dysfunction, bilateral sensorineural hearing loss, and maculopathy, Huntington’s disease, cognitive and movement disorders of the elderly who experience common effects of oxidative stress ([Aso et al. 2012](#)). The process of aging is characterized by the loss of homeostasis, leading to pathologic

formation of reactive oxygen species (ROS), mitochondrial dysfunction, and metabolic unbalance ([Dugger et al. 2017](#)). These pathophenotypes determine abnormal aggregation of specific proteins ([Yanar et al. 2020](#)), given the connection between excessive ROS accumulation and impairment in the proteostasis network. A natural bioactive molecule with an antioxidant property such as ozone (O₃) can be indicated as a potential new strategy to delay neurodegeneration. This hypothesis is based on the evidence regarding the interaction between O₃ and Nrf2 ([Galie et al. 2018](#); [Siniscalco et al. 2018](#); [Re et al. 2014](#); [Vaillant et al. 2013](#)). Molecular mechanisms related to antioxidant/anti-apoptotic/pro-autophagy processes targeted by O₃ administration via an Nrf2 biological pathway.

It is best to implement ozone therapy (O₂-O₃) in an early phase before the potential development of a neurodegenerative pathology ([Scassellati et al. 2020](#)). The O₂ availability affects the expression of different hypoxia-inducible factors (HIFs) and plays the role of a cellular adapter to hypoxia ([Curro et al. 2018](#); [Zhang et al. 2014](#); [Re et al. 2014](#)), leading to the activation of trophic proteins and, consequently, to specific biological processes, including erythropoiesis and angiogenesis ([Zhou et al. 2019](#)).

Antioxidant Property of Ozone (O₃): Oxidative stress is a condition where ROS production exceeds the cellular antioxidant defense system, leading to an imbalance between the two systems, and this may contribute to neuronal damage. It has implications on the pathogenesis and progression of neurodegenerative diseases ([Singh et al. 2019](#)).

Oxidative damage may impair the cells in their structure and function as a result of the reduced activity of mitochondria. The damage is not confined to the brain but is also evident in peripheral cells and tissues, which require a high-energy source such as the heart, muscles, brain, or liver. To function properly, neurons rely on the mitochondria, which produce the energy required for most of the cellular processes, such as neurotransmitter synthesis, including synaptic plasticity.

Mitochondrial dysfunctions cause an increase in ROS for lowered oxidative capacity and antioxidant defense, resulting in increased oxidative damage to protein and lipids, decreased ATP production, and accumulation of DNA damage. Moreover, mitochondrial bioenergetic dysfunction and the release of pro-apoptotic mitochondrial proteins into the cytoplasm initiate a variety of cell death pathways ([Garcia-Escudero et al. 2013](#); [Reutzel et al. 2020](#)).

Ozone therapy stimulates the Krebs cycle by enhancing the oxidative carboxylation of pyruvate and stimulating the production of adenosine triphosphate (ATP) ([Guven et al. 2008](#)).

It causes a significant reduction of nicotinamide adenine dinucleotide (NADH), an increase of the coenzyme A levels to fuel the Krebs cycle, and oxidizes cytochrome C ([Brigelius-Flohe et al. 2011](#); [Elvis et al. 2011](#)).

Ozone(O₃)-influenced pro-oxidative and antioxidant defense biomarkers and their role in aging processes and neurodegenerative disorders (ND). Twenty-nine biomarkers implicated in oxidative stress, in endogenous antioxidant, and in vitagene systems have been identified. These biomarkers have been studied and found modulated after O₃ therapy performed in *in vivo* (human and animal models) samples. Neurodegenerative disorders are characterized by progressive loss of cognitive and behavioral deterioration (Scassellati et al. 2020).

Molecular Mechanisms Involving Ozone Therapy and Their Biological Relevance in Neuroprotection of Nrf2, and the Vitagene Network. Oxidative stress is a condition where ROS and nitrogen (RNS) production exceeds the cellular antioxidant defense system, leading to an imbalance between the two systems and this may contribute to neuronal damage and abnormal neurotransmission. ROS and RNS are also major factors in cellular senescence that leads to an increase in the number of senescent cells in tissues on a large scale ([Liguori et al. 2018](#)). Cellular senescence is a physiological mechanism that stops cellular proliferation in response to damage that occurs during replication. Senescent cells acquire an irreversible senescence-associated secretory phenotype (SASP), involving secretion of soluble factors (interleukins, chemokines, and growth factors), degradative enzymes such as matrix metalloproteases (MMPs), and insoluble proteins/extracellular matrix (ECM) components. When O₃ is administrated, it dissolves immediately in the plasma/serum and it reacts with PUFA (polyunsaturated fatty acids), leading to the formation of the two fundamental messengers: hydrogen peroxide (H₂O₂) as a ROS and 4-hydroxynonenal (4HNE) as a lipid oxidation product (LOP) ([Bocci et al. 1998](#)).

LOPs diffuse into all cells and inform them of minimal oxidative stress. After the oxidative/electrophilic stress challenge (Ishii et al. 2004), other aldehydes (Levonen et al. 2004) induced by O₃ (Galie et al. 2018, Siniscalco et al. 2018, Re et al. 2014, Vaillant et al. 2013) inhibit the Nrf2 conjugation, provoking the nuclear accumulation of Nrf2. This leads to the decreased expression of pro-inflammatory cytokines.

Another mechanism involves casein kinase 2 (CK2), another regulator of Nrf2 activity through its phosphorylation. It has been demonstrated that O₃ influences CK2 levels together with Nrf2 phosphorylation, reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients ([Delgado-Roche et al. 2017](#)). Similarly, O₃ inhibits oxidative stress

through inhibition of the mitogen-activated protein kinase phosphatase (MAPK) 1 signaling pathway ([Wang et al. 2018a](#)).

Oxidative stress is one of the major drivers of protein misfolding that, accumulating and aggregating as insoluble inclusions, can determine neurodegeneration ([Hohn et al. 2020](#); [Knowles et al. 2014](#)). It is known that Nrf2 promotes the clearance of oxidized or otherwise damaged proteins through the autophagy mechanism ([Tang et al. 2019](#)). Interestingly, O₃ can also modulate the degradation protein systems, *not only* via the Nrf2 pathway but also via activation of the AMP-activated protein kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling pathway, as demonstrated ([Zhao et al. 2018](#)).

O₃ can protect against the overproduction of nitric oxide (NO) when NO is a toxic oxidant. NO can rapidly react with other free radicals such as O₂ – the highly reactive oxidant peroxynitrite (ONOO) - and other RNS, which in turn damage the biomolecules (e.g. lipids, protein, DNA/RNA), playing a key role in chronic inflammation and neurodegeneration ([Massaad, 2011](#); [Toda et al. 2009](#)). It has been demonstrated that O₃ downregulates inducible nitric oxide synthase (iNOS), which generates NO ([Manoto et al. 2018](#); [Smith et al. 2017](#)) *via* NF-κB signaling.

CO acts as an inhibitor of another important pathway, NF-κB (nuclear factor kappa B subunit 1) signaling, which leads to the decreased expression of pro-inflammatory cytokines, while bilirubin also acts as an important lipophilic antioxidant. Furthermore, HO-1 directly inhibits pro-inflammatory cytokines and activates anti-inflammatory cytokines, leading to a balancing of the inflammatory process ([Ahmed et al. 2017](#)). Our research group confirmed that mild ozonization, tested on in vitro systems, induced modulation of genes including HO-1 ([Scassellati et al. 2017](#)),

In addition, Nrf2 also regulates the constitutive and inducible expression of antioxidants including, but not limited to, Superoxide Dismutases (SOD), Glutathione Peroxidase (GSH-Px), Glutathione-S-Transferase (GST), Catalase (CAT), and NADPH quinone oxidoreductase 1 (NQO1), phase II enzymes of drug metabolism and HSP ([Galie et al. 2018](#), [Bocci et al. 2015](#), [Pedruzzi et al. 2012](#)).

In this context, Nrf2 is considered a hormetic-like pathway (Calabrese et al. 2010). It has widely been reported that the activation of Nrf2 by several different mechanisms (calorie

restriction, physical exercise, polyphenols) can be a way to improve health due to its transcriptional modulation on the vitagene network. Nrf2 is strongly implicated in aging processes (Zhang et al. 2015; Schmidlin et al. 2019; Silva-Palacios et al. 2018). These conditions share common mechanisms, and the results represent a first attempt to structure Nrf2 as a common therapeutic medicine approach. Research on the antioxidant activities of O₃ correlated with the interaction with Nrf2 (Galie et al. 2018; Siniscalco et al. 2018; Re et al. 2014; Vaillant et al. 2013). Different antioxidants can combat many associated pathologies, including neurodegenerative disorders (Leri et al. 2020; Calabrese 2020). The mechanisms of the positive effects of O₃ are attributed not only to up-regulation of cellular antioxidant enzyme activity, but also to the activation of the immune and anti-inflammatory systems, modulation of NPRL3 inflammasome, action on the proteasome, enhancement in the release of growth factors from platelets, improvement in blood circulation and O₂ delivery to damaged tissues, and enhancement of general metabolism (Scassellati et al. 2020).

The gradual escalation of the ozone dose enhances cerebral blood flow, improves metabolism, and corrects chronic oxidative stress. Neuronal cells may reactivate the synthesis of antioxidant enzymes, which is crucial to normalize the redox state and avoid cell death. The local induction of haeme oxygenase-1 played a critical role in reducing oxidative damage. The enzyme caused the local release of CO and bilirubin that acts as a potent antioxidant of peroxynitrite (Clavo et al. [2004](#)). The trace amounts can pass through the blood-brain barrier to reach the sites of neurodegeneration and upregulate the cellular synthesis of antioxidant enzymes, which is a crucial step towards readjusting the impaired cell redox system. Neurodegenerative disorders affect approximately 50 million people globally and have a terrific and increasingly negative social-economic impact on families and society. A better understanding of degenerative events and the effects of ozone therapy during the early stage of the disease may be able to slow down the demise of critical populations of neurons and thus provide patients with a better quality of life through ozone therapy. The use of ozone in the treatment of various diseases can have a therapeutic effect, provided that the correct dose is administered at the right time interval and depending on the antioxidant capacity of the tissue exposed, as well as ensuring the concentration is used within a non-toxic range. The versatility of ozone therapy is due to the cascade of ozone-derived compounds able to act on several targets leading to a multifactorial correction of various pathological conditions. Ozone therapy can improve well-being and delay the negative effects of aging. The aging process is essentially linked to the balance of oxidants and antioxidants, advanced glycation end

products (AGE), the role of genes and the immune system, the importance of telomeres and telomerase, hormones, nutrition, environmental factors, and certain other factors. Stem cell therapy, virtual reality rehabilitation, electromagnetic fields, and ozone therapy are among the therapeutic approaches in the treatment of neurodegenerative disorders ([Mitrečić et al. 2020](#)).

Ozone Autohaemotherapy Induces Cerebral Metabolic Changes in Multiple Sclerosis Patients.

The oxygenated hemoglobin concentration is increased and the chronic oxidative stress level typical of MS sufferers is reduced ([Molinari et al. 2014](#)). Ozone has an effect on biomarkers of oxidative stress and inflammation, it significantly improves the activity [of antioxidant enzymes](#) and increases the reduced [cellular glutathione levels](#), and demonstrates antioxidant and [anti-inflammatory](#) effects.

Ozone promotes Nrf2 phosphorylation, reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients ([Delgado-Rosche et al. 2017](#)).

[Mechanisms of vascular pathophysiology in multiple sclerosis patients treated with ozone therapy demonstrate revascularisation and regeneration of the blood-brain barrier as a result of immunoreactive glial cells coming into contact with blood vessel walls during ozone therapy](#) ([Ameli et al. 2019](#); [Biomed 2019](#)). The cerebrovascular system enhanced by ozone autohemotherapy in multiple sclerosis patients increases brain metabolism and helps them recover from the lower activity levels that predominate in MS patients ([Molinari et al. 2017](#)). At both primary and chronic stages of MS, antioxidant therapy is an active approach to disease progression. O₃ therapy increases total tissue-oxygen levels in patients with multiple sclerosis. Ozone therapy is a therapeutic alternative for patients with multiple sclerosis ([Molinari et al. 2014](#); [Simonetti et al. 2014](#)).

Ozone therapy applied in acute ischemic stroke increases blood oxygen saturation, improves blood circulation, activates erythrocyte metabolism, improves tissue oxygenation and oxygen supply, restores cell function, promotes oxygen metabolism, and induces thrombolysis by hydrogen peroxide (H₂O₂) formation ([Qiu et al. 2021](#)). Ozone was administered daily via rectal inflation (at an ozone concentration of 40 mg/l and 200 ml) for 15 days. In the clinical phase, an improvement in the quality of life was recorded in 80% of patients treated with ozone therapy [Qiu et al. 2021](#)). Ozone therapy has certain therapeutic benefits for ischemic stroke patients. [Jing Qiu, Hui-sheng Chen](#) (2016) reported that ozonated autohemotherapy substantially improved neurological function in stroke patients.

Neurological Deficits Treated with Ozone Therapy. Trigeminal neuralgia, postherpetic neuralgia, meningitis, cervical myelopathy, demyelinating of nerves. Acoustic neuroma, muscular neuropathy, and parkinsonism have shown satisfactory improvements (Kakkad 2018).

The treatment of trigeminal neuralgia with percutaneous ozone and injections into the Gasserian ganglion has been shown to have positive long-term effects on pain (An et al. 2018; Gao et al. 2020).

The treatment of phantom limb pain with ozone injection into the nerve root in the stump was met with positive results (Li et al. 2020).

Ozone therapy in patients with pain secondary to chemotherapy-induced peripheral neuropathy with cancer of the colon and rectum treated with oxaliplatin and rectal insufflation sessions of O₃/O₂ as part of the ongoing **randomized controlled trial (O3NPIQ) (O3NPIQ) 2020** (Clavo et al. 2019). Chemotherapy-induced peripheral neuropathy decreases the quality of life of patients and can lead to a decrease in and interruption of chemotherapy treatment. Potential pathophysiological mechanisms involved in chemotherapy include chronic oxidative stress and consequent increases in free radicals and pro-inflammatory cytokines. Several antioxidant-based therapies have been tested. On the other hand, ozone therapy can elicit an adaptive antioxidant and anti-inflammatory response that could prove to be useful (Clavo et al. 2021).

Ozone therapy in cerebral ischemia and hypometabolism in meningioma treated by stereotactic radiosurgery. Following ozone autohemotransfusion treatment, there was an improvement in brain perfusion and metabolism, as demonstrated by SPECT and PET scans (Clavo et al. 2011). Rectal ozone therapy showed positive effects of improving neurorehabilitation in children with infratentorial ependymoma (Mašán & Golská 2017).

Ozone therapy of resistant meningitis in infants – a mixture of ozone gas with pure oxygen was used to treat resistant meningitis in infants with hydrocephalus and the infection was cured (Dahhan 2015).

Endolumbal ozone therapy in the treatment of patients with a complicated spinal injury in the acute period improved neurological symptoms (Yuldashev et al. 2020).

In the treatment of lumbar discopathy, ozone therapy is used with verified clinical benefits in the treatment of lumbar disc damage. Ozone application methods can be administered

paravertebrally, juxtaforaminally, intradiscally ([De Oliveira – Magalhaes](#) et al. 2012; Mašán 2017; [Li](#) et al. 2020; Yuldashev et al. 2020).

CONCLUSION

Ozone therapy is a biological treatment method with a wide range of applications in medicine. The versatility of ozone therapy is due to the cascade of ozone-derived compounds able to act on several targets leading to a multifactorial correction of pathological conditions. O₃ therapy induces moderate oxidative stress when interacting with lipids, increases endogenous production of antioxidants, local perfusion, and oxygen delivery, as well as enhances immune responses. Oxidative stress occurs when there is an imbalance between free radical formation and antioxidant defense and is associated with damage to lipids, proteins, and nucleic acids. Ozone is being examined as a master regulator of multiple cytoprotective responses, as a key actor across a wide range of diseases, and as a therapeutic objective for aging and aging-associated disorders. It provides scientific evidence for the application of oxygen-ozone (O₂-O₃) in the treatment of neurological diseases. Oxidative stress is currently thought to play a significant role in the development of inflammatory diseases, ischemic diseases, hypertension, Alzheimer's disease, Parkinson's disease, muscular dystrophy, and many others.

The versatility of ozone therapy is due to the cascade of ozone-derived compounds able to act on several targets leading to a multifactorial correction of various pathological conditions, as well as cardiovascular, peripheral vascular, neurological, orthopedic conditions, skin diseases, wound healing, diabetes, and lung diseases, including the pandemic disease caused by the COVID-19 coronavirus. Ozone therapy also promotes tissue perfusion, immunomodulatory effect, energy effect of the body, and has regenerative and reparative properties. It appears to be a potentially effective treatment method. When the correct dose is administered, no side effects occur. Further clinical and experimental studies will be needed to determine the optimal administration schedule and to evaluate the potential combination of ozone therapy with other therapies to increase the effectiveness of treatment.

REFERENCES

1. Ademowo OS, Dias HKI, Milic I, Devitt A, Moran R, Mulcahy R, Howard AN, Nolan M, Griffiths HR. (2017). Phospholipid oxidation and carotenoid supplementation in

- Alzheimer's disease patients. *Free Radic. Biol. Med.* 108: 77–85. doi: 10.1016 / j.freeradbiomed.2017.03.008.
2. Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. (2017). Nrf2 signaling pathway: Pivotal roles in inflammation. *Biochim Biophys Acta Mol Basis Dis.* 1863(2): 585-597. doi: 10.1016/j.bbadis.2016.11.005.
 3. Altman N. *Healing Arts* (2007). The oxygen prescription : the miracle of oxidative therapies. Healing Arts Press, Rochester, Vermont 2007. ISBN1-59477- 4.
 4. Ameli J, Banki A, Khorvash F, Simonetti V, Jafari NJ, Izadi M (2019). Mechanisms of pathophysiology of blood vessels in patients with multiple sclerosis treated with ozone therapy: a systematic review. *Acta Biomed.* 90: 213–217. doi: 10.23750/abm.v90i3.7265.
 5. An JX, Liu H, Chen RW, Wang Y, Zhao WX, Eastwood D, Williams JP (2018). Computed tomography-guided percutaneous ozone injection of the Gasserian ganglion for the treatment of trigeminal neuralgia. 11: 255-263. doi.org/10.2147/JPR.S140369.
 6. Aso E, Lomoio S, Lopez-Gonzalez I, Joda L, Carmona M, Fernandez-Yague N, Moreno J, Juves S, Pujol A, Pamplona R, Portero-Otin M, Martin V, Diaz M, Ferrer I (2012). Amyloid generation and dysfunctional immunoproteasome activation with disease progression in animal model of familial Alzheimer's disease. *Brain Pathol.* 22: 636–653. doi: 10.1111 / j.1750-3639.2011.00560.x.
 7. Barone P, Santangelo G, Morgante L , Onofri M, Meco G, Abbruzzese G, Bonuccelli U, Cossu G , Pezzoli G , Stanzione P, Lopiano L , Antonini A , Tinazzi M. (2015). A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients. *Eur J Neurol.* 22(8): 1184-91. doi: 10.1111/ene.12724.
 8. Bilge A, Ozturk O, Adali Y, Ustebay S. (2018). Could Ozone Treatment be a Promising Alternative for Osteomyelitis? an Experimental Study. *Acta Ortop. Bras.* 26: 67–71. doi: 10,1590 / 1413-785220182601179926.
 9. Biomed A (2019). Mechanisms of pathophysiology of blood vessels in patients with multiple sclerosis treated with ozone therapy: a systematic review . 90 (3): 213–217. doi: 10.23750/abm.v90i3.7265.
 10. Bocci V (2010). The Potential Toxicity of Ozone: Side Effects and Contraindications of Ozonotherapy. *OZONE.* 75-84. doi:10.1007/978-90-481-9234-2_7.
 11. Bocci V, Larini A, Micheli V. (2005). Restoration of normoxia by ozone therapy may control neoplastic growth: a review and a working hypothesis. *J Altern Complement Med.* 11(2): 257-65. doi: 10.1089/acm.2005.11.257.
 12. Bocci V, Valacchi G (2015). Nrf2 activation as target to implement therapeutic treatments. *Frontiers in Chemistry.* 3: 4. doi: 10.3389/fchem.2015.00004.
 13. Bocci V, Valacchi G, Corradeschi F, Fanetti G. (1998). Studies on the biological effects of ozone: 8. Effects on the total antioxidant status and on interleukin-8 production. *Mediators Inflamm.* 7(5): 313–317. doi: 10.1080/09629359890820.
 14. Bocci V, Zanardi I, Huijberts MS, Travagli V. (2011). Diabetes and chronic oxidative stress. A perspective based on the possible usefulness of ozone therapy. *Diabetes Metab Syndr.* 5: 45–49. doi: 10.1016 / j.dsx.2010.05.014.
 15. Bocci VA (2006). Tropospheric ozone toxicity vs. usefulness of ozone therapy. *Arch Med Res* 2007, Feb; 38(2): 265-267. doi: 10.1016/j.arcmed.2006.09.011.
 16. Bocci VA, Zanardi I, Travagli V. (2011). Ozone acting on human blood yields a hormetic dose-response relationship. *J Transl Med.* 9: 66. doi: 10,1186 / 1479-5876-9-66.
 17. Bocci VA. (2006) Scientific and Medical Aspects of Ozone Therapy. State of the Art. *Archives of Medical Research*, 37, 425-435. doi.org/10.1016/j.arcmed.2005.08.006

18. Braidy N, Izadi M, Sureda A, Jonaidi-Jafari N, Banki A, Nabavi SF, Nabavi S.M (2018). Therapeutic relevance of ozone therapy in degenerative diseases: Focus on diabetes and spinal pain. *J. Cell. Physiol.* 233: 2705–2714. doi: 10.1002/jcp.26044.
19. Brigelius-Flohe R, Flohe L. (2011). Basic principles and emerging concepts in the redox control of transcription factors. *Antioxid.Redox Signal.* 15: 2335–2381. doi: 10.1089/ars.2010.3534.
20. Calabrese EJ. (2020). Hormesis and Ginseng: Ginseng Mixtures and Individual Constituents Commonly Display Hormesis Dose Responses, Especially for Neuroprotective Effects. *Molecules.* 2020; 25 doi: 10.3390/molecules25112719.
21. Calabrese EJ. (2016). Preconditioning is hormesis part II: How the conditioning dose mediates protection: Dose optimization within temporal and mechanistic frameworks. *Pharmacol.Res.* 2016; 110: 265–275. doi: 10.1016/j.phrs.2015.12.020.
22. Calabrese V, Cornelius C, Calabrese EJ, Mattson MP (2010). Cellular stress responses, the hormesis paradigm, and vitagenes: novel targets for therapeutic intervention in neurodegenerative disorders. *Antioxid. Redox Signal.* 13: 1763–1811. doi: 10.1089/ars.2009.3074.
23. Caliskan B, Guven A, Ozler M, CAYCI T, OZCAN A, BEDIR O, SURER I, KORKMAZ A. (2011). Ozone therapy prevents renal inflammation and fibrosis in a rat model of acute pyelonephritis. *Scand J Clin Lab Invest.* 2011; 71: 473–480. doi: 10.3109 / 00365513.2011.587022.
24. Clavo B, Martínez-Sánchez G, Rodríguez-Esparragón F, Rodríguez-Abreu D, Galván S; Aguiar-Bujanda D, Díaz-Garrido JA, Cañas S, Torres-Mata LB, Fabelo H; et al. (2021). Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial. *Int. J. Mol. Sci.* 22: 2802. [https://doi.org/ 10.3390/ijms22062802](https://doi.org/10.3390/ijms22062802).
25. Clavo B, Rodríguez-Esparragón F, Rodríguez-Abreu D, Martínez-Sánchez G, Lloncop P, Aguiar-Bujanda D, Leandro Fernández-Pérez L, a Santana-Rodríguez S (2019). Modulation of Oxidative Stress by Ozone Therapy in the Prevention and Treatment of Chemotherapy-Induced Toxicity: Review and Prospects. 8(12): 588.
26. Clavo, B, Suarez G, Aguilar Y, Gutierrez D, Ponce P, Cubero A, Robaina F, Carreras JL (2011). Brain ischemia and hypometabolism treated by ozone therapy. [PubMed]. 18(5): 283-7. doi: 10.1159/000333795.
27. Clavo B, Juan L Pérez L, López L, Suárez G, Lloret M, Rodríguez V, Macías D, Santana M, Hernández MA, Oliva RM, Robaina F (2004). Ozone Therapy for Tumor Oxygenation: a Pilot Study. [PubMed]. *Evid Based Complement Alternat Med.* 1(1): 93-98. doi: 10.1093/ecam/neh009.
28. Currò M, Russo T, Ferlazzo N, Caccamo D, Antonuccio P, Arena S, Parisi S, Perrone P, Ientile R, Romeo C, Impellizzeri P (2018). Anti-Inflammatory and Tissue Regenerative Effects of Topical Treatment with Ozonated Olive Oil/Vitamin E Acetate in Balanitis Xerotica Obliterans. *Molecules.* 23(3): 645. doi: 10.3390/molecules23030645. PMID: 29534008; PMCID: PMC6017296.
29. Dahhan M KB (2015). Cases Study of the Effectiveness of Ozone Gas Therapy on the Treatment of Resistant Meningitis in Infants with Hydrocephalus. *J Neurol Stroke* 3(5): 00107. doi: 10.15406/jnsk.2015.03.00107.
30. Dattilo S, Mancuso C, Koverech G, Di Mauro P, Ontario ML, Petralia CC, Petralia A, Maiolino L, Serra A, Calabrese EJ, Calabrese V (2015). Heat shock proteins and hormesis in the diagnosis and treatment of neurodegenerative diseases. *Immun Ageing.* 12: 20. doi: 10.1186/s12979-015-0046-8. PMID: 26543490; PMCID: PMC4634585.

31. De Oliveira Magalhaes FN, Dotta L, Sasse A, MJ, Erich T Fonoff. (2012). Ozone therapy as a treatment for low back pain secondary to herniated disc: a systematic review and meta-analysis of randomized controlled trials. *Pain Physician*. 15(2): E115-29.
32. Delgado-Roche L, Riera-Romo M, Mesta F, Hernandez-Matos Y, Barrios JM, Martinez-Sanchez G, Al-Dalaien SM. (2017). Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. *Eur. J. Pharmacol.* 811: 148–154. doi: 10.1016/j.ejphar.2017.06.017.
33. Delgado-Roche L, Riera-Romo M, Mesta F, Hernández-Matos Y, Juan M. Barrios JM, Martínez-Sánchez G, Al-Dalaien SM (2017). Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. [PubMed]. 2017.15;811:148-154. doi: 10.1016/j.ejphar.2017.06.017.
34. Dugger BN, Dickson DW (2017). Pathology of Neurodegenerative Diseases. *Cold Spring Harb Perspect Biol*. 9(7): a028035. doi: 10.1101/cshperspect.a028035.
35. Elvis AM, Ekta JS (2011). Ozone therapy: A clinical review. *J Nat Sci Biol Med*. 2(1): 66-70. doi: 10.4103/0976-9668.82319.
36. Fernández-Leon OS, Ajamieh HH, Berlanga J, et al. (2008). Ozone oxidative preconditioning is mediated by A1 adenosine receptors in a rat model of liver ischemia/reperfusion. *Transpl Int*. 21: 39–48. doi: 10.1111 / j.1432-2277.2007.00568.x
37. Galie M, Costanzo M, Nodari A, Boschi F, Calderan L, Mannucci S, Covi V., Tabaracci G., Malatesta M. (2018). Mild ozonisation activates antioxidant cell response by the Keap1/Nrf2 dependent pathway. *Free Radic. Biol. Med*. 124: 114–121. doi: 10.1016/j.freeradbiomed.2018.05.093
38. Gao L, Chen R-W, Williams JP, Li T, Han W-J, Qian-Nan Zhao Q-N, Yong Wang Y, An J-X (2020). Efficacy and Safety of Percutaneous Ozone Injection Around Gasserian Ganglion for the Treatment of Trigeminal Neuralgia: A Multicenter Retrospective Study. *Pain Res*. 13: 927–936. Published online 2020 May 4. doi: 10.2147/JPR.S232081.
39. García-Escudero V, Martín-Maestro P, Perry G, Avila J (2013). Deconstructing mitochondrial dysfunction in Alzheimer disease. *Oxid Med Cell Longev*. 2013: 162152. doi: 10.1155/2013/162152.
40. González R, Borrego A, Zamora Z, Romay C, Hernández F, Menéndez S, Montero T, Rojas E (2004). Reversion by ozone treatment of acute nephrotoxicity induced by cisplatin in rats. *Mediators Inflamm*. 13(5-6): 307-312. doi: 10.1080/09629350400008836.
41. Gulmen S, Kurtoglu T, Meteoglu I, Kaya S, Okutan H. (2013). Ozone therapy as an adjunct to vancomycin enhances bacterial elimination in methicillin resistant *Staphylococcus aureus* mediastinitis. *J Surg Res*. 185: 64–69. doi: 10.1016 / j.jss.2013.05.085.
42. Guven A, Gundogdu G, Sadir S, Topal T, Erdogan E, Korkmaz A, Surer I, Ozturk H. (2008). The efficacy of ozone therapy in experimental caustic esophageal burn. *J. Pediatr. Surg*. 43: 1679–1684. doi: 10.1016/j.jpedsurg.2008.01.064.
43. Higdon AN, Landar A, Barnes S, Darley-USmar VM (2012). The electrophile responsive proteome: integrating proteomics and lipidomics with cellular function. *Antioxid Redox Signal*. 17(11): 1580-9. doi: 10.1089/ars.2012.4523.

44. Hohn A, Tramutola A, Cascella R. (2020). Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. *Oxid Med Cell Longev.* 2020 (Special issue): Article ID 5497046. doi.org/10.1155/2020/5497046
45. Hu J, Ma H, Zhu S, Cai X, Yan K, Lu HD. (2018). Visual Motion Processing in Macaque V2. *Rec.* Oct. 2016, 2018. Publ.: Oct.2018. doi.org/10.1016/j.celrep.2018.09.014.
46. Chang JD, Lu HS, Chang YF, Wang D. (2005). Ameliorative effect of ozone on cytokine production in mice injected with human rheumatoid arthritis synovial fibroblast cells. *Rheumatol Int.* 26: 142–151. doi: 10.1007/s00296-004-0526-1.
47. Chang ET, SmedbyShumin KE, Zhang M, Hjalgrim H, Melbye M, Ost A, Glimelius B, Wolk A, Adami HO. (2005). Dietary factors and risk of non-hodgkin lymphoma in men and women. *Cancer Epidemiol Biomarkers Prev.* 2005 Feb;14(2):512-20. doi: 10.1158/1055-9965.EPI-04-0451.
48. Inal M, Dokumacioglu A, Ozcelik E, Ucar O (2011).The effects of ozone therapy and coenzyme Q₁₀ combination on oxidative stress markers in healthy subjects. *Ir J Med Sci.* 180(3): 703-7. doi: 10.1007/s11845-011-0675-7.
49. Ishii T, Itoh K, Ruiz E, Leake DS, Unoki H, Yamamoto M, Mann GE. (2004). Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. *Circ. Res.* 94 (5): 609–616. <https://doi.org/10.1161/01.RES.0000119171.44657.45>
50. Izadi M, Kheirjou R, Mohammadpour R, Aliyoldashi MH, Moghadam SJ, Khorvash F, Jafari NJ, Shirvani S, Khalili N. (2019). Efficacy of comprehensive ozone therapy in diabetic foot ulcer healing. *Diabetes Metab Syndr.* 13(1): 822–825. doi: 10.1016/j.dsx.2018.11.060.
51. Kakkad VJ (2018). Neurological deficits ltreated with Ozone Therapy. *Proceedings of the 5Th WFOT Meeting; 2016 Nov 18-20; Mumbai, India. J Ozone Therapy.* 2(2). doi:10.7203/jo3t.2.2.2018.11155.
52. Kall E, ProseÂe1R, Winters M, van der Kamp J, (2017). Does implicit motor learning lead to greater automatization of motor skills compared to explicit motor learning? A systematic review. *Systematic review.* Rec.: October 31, 2017, Published: September 5, 2018, PLoS ONE 13(9): Journal.pone.0203591 doi.org/10.1371/.
53. Knowles TP, Vendruscolo M, Dobson CM. (2014). The amyloid state and its association with protein misfolding diseases. *Nat Rev Mol Cell Biol.* 15 (6): 384–396. doi: 10.1038/nrm3810.
54. Lahodny J. (2021). Ozonanwendungen [online]. 2021. cit. 2021-02-03). Available on the Internet: <https://dr-lahodny.at/ozonanwendungen/>
55. Leri M, Scuto M, Ontario ML, Calabrese V, Calabrese EJ, Bucciantini M, Stefani M (2020). Healthy Effects of Plant Polyphenols: Molecular Mechanisms. *Int J Mol Sci.* 21(4): 1250. doi: 10.3390/ijms21041250.
56. Levonen AL, Landar A, Ramachandran A, Ceaser EK, Dickinson DA, Zanoni G, Morrow JD, Darley-Usmar VM. (2004). Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. *Biochem. J.* 378 (Pt2): 373–382. Doi: 10.1042/BJ20031049.
57. Li J, Li T, Li G, Liu H, Zhang X. (2020). Selective nerve root injection of ozone for the treatment of phantom limb pain: Three case reports. 99(16): e19819. doi: 10.1097/MD.00000000000019819.
58. Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, Abete P. (2018). Oxidative stress, aging, and diseases.

- Clin. Interv. Aging 13, 757–772. Clin Interv Aging. 13: 757–772. doi: 10.2147/CIA.S158513.
59. Madej P, Plewka A, Madej JA, et al. (2007). Ozonotherapy in an induced septic shock. I. Effect of ozonotherapy on rat organs in evaluation of free radical reactions and selected enzymatic systems. *Inflammation*. 30: 52–58. doi: 10.1007 / s10753-007-9021-7.
 60. Mancuso C, Capone C, Ranieri SC, et al (2008). Bilirubin as an endogenous modulator of neurotrophin redox signaling. *J Neurosci Res*. (10)86: 2235–2249.
 61. Mancuso C, Pistrutto G, Tringali G, Grossman AB, Preziosi P, Navarra P (1997). Evidence that carbon monoxide stimulates prostaglandin endoperoxide synthase activity in rat hypothalamic explants and in primary cultures of rat hypothalamic astrocytes. *Brain Res Mol Brain Res.PubMed*. 45(2): 294-300. doi: 10.1016/s0169-328x (96)00258-6.
 62. Mancuso C. (2017). Bilirubin and brain: a pharmacological approach. *Neuropharmacology*. 118:113–123. doi: 10.1016 / j.neuropharm.2017.03.013.
 63. Manoto SL, Maepa MJ, Motaung SK. (2018). Medical ozone therapy as a potential treatment modality for regeneration of damaged articular cartilage in osteoarthritis. *Saudi J Biol Sci*. 25: 672–679. doi: 10.1016/j.sjbs.2016.02.002
 64. Massaad CA (2011). Neuronal and vascular oxidative stress in Alzheimer's disease *Curr Neuropharmacol*. PubMed. 2011 Dec;9(4):662-73. doi: 10.2174/157015911798376244.
 65. Mašán J, Golská S. (2017). Infratentorial ependymoma of a two-year-old child, neurorehabilitation and ozone therapy. In: *Neurorehab 2017*. print.: ALMIL, p. 34-35. ISBN 978-80-971938-4-3.
 66. Mašán J. (2017). Use ozone in neurology. In: *Neurorehab 2017*. print. Almil. Page:120-126. ISBN 978-80-85659-84-9.
 67. Mašán J. (2018). Ozone therapy in traumatology. In: *Pitfalls and complications in the treatment of fractures* . print.: Galén. p. 396-400. 2018. ISBN 978-80-7492-393-7.
 68. Mitrečić D , Petrović DJ, Stančin P, Isaković J, Zavan B, Tricarico G, Kujundžić Tiljak M, Di Luca M. (2020). How to face the aging world - lessons from dementia research . *Croat Med J*. 61(2): 139-146. doi: 10.3325/cmj.2020.61.139.
 69. Molinari F, Rimini D, Liboni W, et al. (2017). Cerebrovascular pattern improved by ozone autohemotherapy: an entropy-based study on multiple sclerosis patients. *Med Biol Eng Comput*. 55: 1163–1175. doi: 10,1007 / s11517-016-1580-z.
 70. Molinari F, Simonetti V, Franzini M, Pandolfi S, Vaiano F, Valdenassi L, Liboni W (2014). Ozone autohemotherapy induces long-term cerebral metabolic changes in multiple sclerosis patients . 27(3): 379-89. doi: 10.1177/039463201402700308.
 71. Pedruzzi LM, Stockler-Pinto MB, Leite JrM, Mafra D. (2012). Nrf2-keap1 system versus NF-kappaB: the good and the evil in chronic kidney disease? *Biochimie*. 94 (12): 2461-2466. doi: 10.1016/j.biochi.2012.07.015
 72. Pryor R, Norvaisas P, Marinos G, Best L, Thingholm LB, Quintaneiro LM, De Haes W, Esser D, Waschina S, Lujan C, Smith RL, Scott TA, Martinez-Martinez D, Woodward O, Bryson K, Laudes M, Lieb W, Houtkooper RH, Franke A, Temmerman L, Bjedov I, Cocheme HM, Kaleta C, & Cabreiro F (2019). Host-Microbe-Drug-Nutrient Screen Identifies Bacterial Effectors of Metformin Therapy. *Cell*. doi:10.1016/j.cell.2019.08.003.
 73. Qiu A, Zhang H, Wang Ch, Chong YS, Shek LP, Gluckman PD, Meaney MJ, Fortier MV & Wu Y. (2021). Canonical TGF- β signaling regulates the relationship between

- prenatal maternal depression and amygdala development in early life. *Translational Psychiatry*, **Volume 11**, Article Number: 170 (2021). Published: 15 March 2021.
74. Qiu J, Chen HS (2016). Efficacy and safety of ozone therapy administered by autologous blood transfusion for acute ischemic stroke: study protocol for a multi-center open-label large-sample parallel randomized controlled trial. *Asia Pac. Journal: Nerv Syst Dis.* IP: 213.215.84.6]. 1(2): 37-42. doi: 10.4103/2468-5577.181233.
 75. Ramirez-Acuña JM, Cardenas-Cadena SA, Marquez-Salas PA, Garza-Veloz I, Perez-Favila A, Cid-Baez MA, Flores-Morales V, Martinez-Fierro ML (2019). Diabetic Foot Ulcers: Current Advances in Antimicrobial Therapies and Emerging Treatments. *Antibiotics (Basel)*. 8(4): 193. doi: 10.3390/antibiotics8040193.
 76. Rattan S, Demirovic D (2009). Hormesis can and does work in humans. [PubMed]. *Dose Response*.8(1): 58-63. doi: 10.2203/dose-response.09-041.
 77. Re L, Martinez-Sanchez G., Bordicchia M, Malcangi G, Pocognoli A, Morales-Segura MA, Rothchild J, Rojas A (2014). Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. *Eur. J. Pharmacol.* 742: 158–162. doi: 10.1016/j.ejphar.2014.08.029.
 78. Reutzel M, Grewal R, Dilberger B, Silaidos C, Joppe A, Eckert GP (2020). Cerebral Mitochondrial Function and Cognitive Performance during Aging: A Longitudinal Study in NMRI Mice. *Oxid Med Cell Longev.* 2020: 4060769. doi: 10.1155/2020/4060769.
 79. Rowen RJ (2018). Ozone therapy in conjunction with oral antibiotics as a successful primary and sole treatment for chronic septic prosthetic joint: review and case report. *Med Gas Res.* 8(2): 67-71. doi: 10.4103/2045-9912.235139.
 80. Scassellati C, Ciani M, Galoforo A.C, Zanardini R, Bonvicini C, Geroldi C (2020). Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment. *Mech. Ageing Dev.* 186: 111210. doi: 10.1016/j.mad.2020.111210.
 81. Scassellati C, Costanzo M, Cisterna B, Nodari A, Galie M, Cattaneo A, Covi V, Tabaracci G, Bonvicini C, Malatesta M. (2017). Effects of mild ozonisation on gene expression and nuclear domains organization in vitro. *Toxicol In Vitro.* 44: 100-110. doi: 10.1016/j.tiv.2017.06.021.
 82. Scassellati C, Galoforo AC, Bonvicini C, Esposito C, Ricevuti G (2020). Ozone: a natural bioactive molecule with antioxidant property as potential new strategy in aging and in neurodegenerative disorders. *Ageing Res Rev.* 63:101138. doi: 10.1016/j.arr.2020.101138.
 83. Schmidlin CJ, Dodson MB, Madhavan L, Zhang DD (2019). Redox regulation by NRF2 in aging and disease. *Free Radic. Biol. Med.* 134: 702–707. doi: 10.1016 / j.freeradbiomed.2019.01.016.
 84. Silva-Palacios A, Ostolga-Chavarria M, Zazueta C, Konigsberg M. (2018). Nrf2: Molecular and epigenetic regulation during aging. *Ageing Res. Rev.* 47:31–40. doi: 10.1016/j.arr.2018.06.003.
 85. Simonetti, V, Liboni W, Molinari F (2014). Why Ozone Therapy in Multiple Sclerosis?. *Revista Española de Ozonoterapia.* 4(1): 51-68. ISSN: 2174-3215
 86. Singh A, Kukreti R, Saso L, Kukreti S (2019). Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. *Molecules.* 24 doi: 10.3390/molecules24081583.
 87. Siniscalco D, Trotta MC, Brigida AL, Maisto R, Luongo M, Ferraraccio F, D'Amico M, Di Filippo C (2018). Intraperitoneal Administration of Oxygen/Ozone to Rats Reduces the Pancreatic Damage Induced by Streptozotocin. *Biology (Basel)* 7(1): 10. doi: 10.3390/biology7010010.

88. Smith NL, Wilson AL, Gandhi J, Vatsi S, Khan SA (2017). Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. *Med. Gas Res.* 7(3): 212-219. doi: 10.4103/2045-9912.215752.
89. Tang, T, D. Shindell, G. Faluvegi, G. Myhre, D. Olivié, A. Voulgarakis, M. Kasoar, T. Andrews, O. Boucher, P.M. Forster, Ø. Hodnebrog, T. Iversen, A. Kirkevåg, J.-F. Lamarque, T. Richardson, B.H. Samset, C.W. Stjern, T. Takemura, and C. Smith. (2019). Comparison of effective radiative forcing calculations using multiple methods, drivers, and models. *J. Geophys. Res. Atmos.*, 124, no. 8, 4382-4394, doi:10.1029/2018JD030188.
90. Tirelli U, Cirrito C, Pavanello M, Piasentin C, Lleshi A, Taibi R. (2019). Ozone therapy in 65 patients with fibromyalgia: an effective therapy. *Eur. Rev. Med. Pharmacol. Sci.* 23:1786–1788.
91. Toda N, Ayajiki K, Okamura T. (2009). Cerebral blood flow regulation by nitric oxide: recent advances *Pharmacol Rev.* PubMed 2009 Mar;61(1):62-97. doi: 10.1124/pr.108.000547.
92. Vaillant JD, Fraga A, Diaz MT, Mallok A, Viebahn-Hansler R, Fahmy Z, Barbera A, Delgado L, Menendez S, Fernandez OS. (2013). Ozone oxidative postconditioning ameliorates joint damage and decreases pro-inflammatory cytokine levels and oxidative stress in PG/PS-induced arthritis in rats. *Eur. J. Pharmacol.* 714: 318–324. doi: 10.1016/j.ejphar.2013.07.034
93. Valacchi G, Bocci V (2000). Studies on the biological effects of ozone: 11. Release of factors from human endothelial cells. *Mediators Inflamm.* 9:271–276. doi: 10.1080/09629350020027573.
94. Wang L, Chen Z, Liu Y, Du Y, Liu X. (2018). Ozone oxidative postconditioning inhibits oxidative stress and apoptosis in renal ischemia and reperfusion injury through inhibition of MAPK signaling pathway. *Drug Des Devel Ther.* 12: 1293–1301. Doi:147/DDDT.S164927.
95. Yanar K, Atayik MC, Simsek B, Çakatay U (2020). Novel biomarkers for the evaluation of aging-induced proteinopathies. *Biogerontology.* 21(5): 531-548. doi: 10.1007/s10522-020-09878-8.
96. Yuldashev SS, Mamadaliev AM, Aliev MA (2020). Endolumbal Nootropic-Ozone Therapy In Complex Treatment Of Patients With Complicated Spinal Injury In Acute Period. 2020. Shavkiddin S. Yuldashev Abdurakhmon M. Mamadaliev Mansur A. Aliev *Eur J Molec Clin Med.* 7(3): 1571-1576. Online ISSN: 2515-8260.
97. Yuldashev TK, Karimov ET. (2020). Inverse Problem for a Mixed Type Integro-Differential Equation with Fractional Order Caputo Operators and Spectral Parameters. *Journals Axioms*, 2020. Volume 9, Issue 4, doi: 10.3390/axioms9040121
98. Zhang J, Davies KJA, Forman H.J (2015). Oxidative stress response and Nrf2 signaling in aging. *Radic Biol Med.* 88:314–336. doi: 10.1016/j.freeradbiomed.2015.05.036.
99. Zhang J, Guan M, Xie C, Luo X, Zhang Q, Xue Y (2014). Increased growth factors play a role in wound healing promoted by noninvasive oxygen-ozone therapy in diabetic patients with foot ulcers. *Oxid Med Cell Longev.* 2014: 273475. doi: 10.1155/2014/273475.
100. Zhao X, Li Y, Lin X, Wang J, Zhao X, Xie J, Sun T, Fu Z. (2018). Ozone induces autophagy in rat chondrocytes stimulated with IL-1beta through the AMPK/mTOR signaling pathway. *J Pain Res.* 2018 (11): 3003–3017. doi.org/10.2147/JPR.S183594

101. Zhou M, Hou J, Li Y, Mou S, Wang Z, Horch RE, Sun J, Yuan Q (2019). The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model. *Sci. Rep.* 9(1): 6035. doi: 10.1038/s41598-019-41924-5.